Group 1 - The agricultural pesticide sector is experiencing a resurgence, with companies like Lianhua Technology achieving a remarkable performance of 9 gains in 7 days [1] - Other companies in the sector, such as Bestme, Su Li Co., Guangkang Biochemical, Taihe Co., and Yangnong Chemical, have also shown significant increases, with Bestme rising over 10% [1] - Analysts believe that the price of Chlorantraniliprole is expected to see a phase of price increase, contributing to the sector's strength [1] Group 2 - Future regulatory approvals and production supervision for high-risk chemical reactions, such as nitration and chlorination, are expected to become stricter [1] - Leading companies in the chemical industry may benefit from stable production of existing products, as their growth in intermediates and products related to high-risk reactions will be limited [1]

Core Viewpoint - ST Hongtai announced a price adjustment for its 97% chlorantraniliprole product to 300,000 yuan per ton, a more than 40% increase compared to last year's low of 210,000 yuan per ton, primarily due to limited upstream raw material supply and rising costs [1][3]. Industry Overview - Chlorantraniliprole is the world's largest insecticide, with annual global sales exceeding $2 billion. After the expiration of its compound patent in China in August 2022, market prices continued to decline, with a cumulative drop of 34.38% in 2024. However, since 2025, prices have rebounded due to low effective capacity release influenced by intermediates and operating rates, rising to 228,000 yuan per ton on May 25, an increase of 8.57% [3]. - Currently, there are over 100,000 tons per year of chlorantraniliprole production capacity under construction or planning in China, but the progress of planned capacity construction has slowed due to the impact of intermediate K amine supply and declining raw material prices [3]. Market Reaction - Following the price adjustment announcement, the pesticide sector continued to show strength on June 9, with stocks such as Changqing Co. and Guangkang Biochemical hitting historical highs, and ST Hongtai and other stocks also rising [3]. - Analysts generally believe that chlorantraniliprole prices are likely to experience a phase of upward momentum. Future project approvals and production regulations involving hazardous chemical reactions such as nitration and chlorination are expected to become stricter, benefiting leading companies in the chemical industry that can maintain stable production of existing products [3]. Company Responses - Due to changes in market supply dynamics, investor interest in companies involved in chlorantraniliprole has increased, prompting several listed companies to respond. Lianhua Technology stated that it provides advanced intermediates through a CDMO model and does not directly produce the product, indicating limited overall impact on the company. Huailong Co. is steadily advancing its chlorantraniliprole raw material and intermediate project with an annual output of 2,000 tons. Lier Chemical is orderly constructing a 5,000 tons/year production facility. Changqing Co. confirmed that its insecticides are currently in normal production. Liming Co. noted that if chlorantraniliprole supply tightens, it would boost demand for alternatives such as abamectin and methomyl [4].

A股创新药板块持续活跃，众生药业、昂利康涨停，联化科技涨超9%，睿智医药、海辰药业、翰宇药 业等高开。 订阅A股涨停捉妖队 +订阅 订阅A股市场资讯 +订阅 ...

5月下旬至6月初，联化科技（002250.SZ）股价区间涨幅高达95.07%，近一周涨幅达43.18%（收盘价从 8.36元升至11.97元）。造成这家公司股价短时间内井喷的原因其实与山东高密友道化学厂爆炸事件密不 可分。 友道化学是全球最大的氯虫苯甲酰胺原药生产企业，产能达1.1万吨/年，占国内产能50%-60%，占全球 总产能的30%，占全球出口量的58%。爆炸事故使其产能受到冲击，市场预计氯虫苯甲酰胺产能或有缩 减，进而影响其短期供应，需求缺口将造成价格上涨。 联化科技主要从事农药、医药中间体的生产与销售，氯虫苯甲酰胺也是其重要产品之一。另外，友道化 学作为全球最大的氯虫苯甲酰胺原药生产企业，发生爆炸后市场供应格局发生变化，制剂企业为了保生 产必将采购氯虫苯甲酰胺的农药中间体K胺，而联化科技拥有5000吨/年的K胺合法产能，占全球总产能 的41.7%，为目前全球最大的合规产能。或许这是近期联化科技股价井喷的最主要因素。 除去山东高密友道化学厂爆炸的特殊事件外令其股价上涨外，联化科技基本面的改善也是影响股价上升 的因素之一。 2024年，联化科技营业收入为56.77亿元，同比下降11.88%；归母净利润同 ...

Market Performance - A-shares showed strong momentum with major indices rising, Shanghai Composite Index surpassed 3400 points, and ChiNext Index increased over 1% [1] - Hong Kong stocks also performed well, with the Hang Seng Index rising over 1% and returning above 24000 points, while the Hang Seng Tech Index surged nearly 3% [1] - Total market turnover reached approximately 1.31 trillion yuan, an increase of 135.5 billion yuan from the previous trading day [1] Innovative Drug Sector - The innovative drug concept stocks experienced significant gains, with the innovative drug index rising over 4% [2] - Notable stocks included Hai Chen Pharmaceutical, Rui Zhi Pharmaceutical, and others, with nearly 15 related stocks hitting the daily limit or rising over 10% [2] - Since mid-May, innovative drug stocks have shown strong performance, with some stocks like Lianhua Technology increasing nearly 115% in the last nine trading days [2] Industry Developments - The 2025 American Society of Clinical Oncology (ASCO) annual meeting highlighted the competitiveness of Chinese pharmaceutical companies in new drug development [3] - Financial policies introduced since May 7 aim to stabilize market expectations, with a focus on supporting leading pharmaceutical companies with strong dividends [3] Rare Earth Sector - The rare earth sector became active, with the rare earth permanent magnet concept index rising 3.45% [4] - The demand for medium and heavy rare earths is increasing due to the development of industries like robotics and electric vehicles [4] - Supply tightening and policy changes have led to a recovery in rare earth prices, with expectations for continued moderate price increases [5] Elderly Care Robotics - The elderly care robotics sector showed strong performance, with the humanoid robot concept index rising 0.76% [7] - The Ministry of Industry and Information Technology and the Ministry of Civil Affairs announced a pilot program for intelligent elderly care service robots from 2025 to 2027 [7] - The report emphasized the investment value of the robotics sector, highlighting various types of intelligent elderly care robots that cater to different needs [8]

Core Viewpoint - The legal opinion letter from Beijing Jiayuan Law Firm confirms that the 2024 annual general meeting of shareholders for Lianhua Technology Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][5][9]. Group 1: Meeting Procedures - The meeting was convened by the company's board of directors, and a notice detailing the time, location, agenda, voting procedures, and registration methods was published [3][4]. - The meeting took place on June 9, 2025, at 13:30 in Taizhou, Zhejiang Province, and included both on-site and online voting options [4][5]. Group 2: Attendance and Voting - A total of 405 shareholders attended the meeting, representing 911,333,117 shares, with 899,873,217 shares eligible for voting after excluding repurchased shares [5][6]. - The voting process combined both on-site and online methods, with results verified by Shenzhen Securities Information Co., Ltd. [6][9]. Group 3: Voting Results - All proposed resolutions received overwhelming support, with the following key votes: - Resolution 1: 99.7896% approval for the 2024 Board of Directors' work report [6][7]. - Resolution 5: 99.7940% approval for the 2024 profit distribution plan, with 98.2424% approval from minority shareholders [7][8]. - Resolution 9: 99.7929% approval for foreign exchange hedging business [9]. Group 4: Conclusion - The legal opinion concludes that the meeting's convening, attendance qualifications, and voting procedures complied with the Company Law, Shareholders' Meeting Rules, and the company's articles of association, rendering the voting results valid [5][9].

Meeting Overview - The shareholder meeting was held in accordance with the relevant regulations and company bylaws [1][2] - A total of 2 shareholders attended the meeting in person, representing 4,721,070 shares, which is 0.5246% of the total voting shares [2] - Additionally, 403 shareholders participated via online voting, representing 271,025,997 shares, which is 31,769,074 shares or 3.5304% of the total voting shares [2] Voting Results - The resolutions were passed with a majority vote, with the following results: - For the first resolution, 270,455,734 shares voted in favor, accounting for 99.7896% of the votes [2] - For the second resolution, 270,454,234 shares voted in favor, accounting for 99.7890% of the votes [4] - For the third resolution, 270,453,234 shares voted in favor, accounting for 99.7887% of the votes [4] - For the fourth resolution, 270,467,634 shares voted in favor, accounting for 99.7940% of the votes [4] - For the fifth resolution, 243,727,017 shares voted in favor, accounting for 89.9275% of the votes [5] Shareholder Participation - Among the minority shareholders, 31,210,711 shares voted in favor of the resolutions, representing 98.2424% of the minority shareholders present [4] - The voting results indicate a strong consensus among shareholders, with minimal opposition [5]

Core Viewpoint - Company adheres to the CDMO model, aiming to provide long-term, reliable, and competitive chemical solutions to clients rather than just individual products or technologies [1] Group 1 - Company has over ten years of production history for Kamine products, indicating a strong foundation in this area [1] - A significant portion of the company's products are still under patent protection, showcasing its commitment to innovation and proprietary technology [1]

证券代码：002250 证券简称：联化科技 公告编号：2025-033 联化科技股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议时间：2025年6月9日（星期一）13时30分 2、会议地点：浙江省台州市黄岩区世纪大道3号黄岩耀达酒店会议室 3、会议召集人：联化科技股份有限公司董事会 4、会议方式：现场投票与网络投票相结合的方式 6、会议的召集、召开与表决程序符合《公司法》《上市公司股东大会规则》《深 圳证券交易所股票上市规则》等法律、法规及规范性文件和《公司章程》的规定。 （二）会议出席情况 出席现场会议的股东共2名，代表有表决权的股份数4,721,070股，占公司有表决 权股份总数的0.5246%；参加网络投票的股东共403名，代表有表决权的股份数 266,304,927股，占公司有表决权股份总数的29.5936%；参加现场与网络投票的股东 共405名，代表有表 ...

2024年度股东大会的 法律意见书 嘉源(2025)-04-413 北京市嘉源律师事务所 关于联化科技股份有限公司 2024年度股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 北京BEIJING·上海SHANGHAI·深圳SHENZHEN·香港HONG KONG·广州GUANGZHOU·西安XI'AN 致：联化科技股份有限公司 北京市嘉源律师事务所 关于联化科技股份有限公司 北京市嘉源律师事务所（以下简称"本所"）接受联化科技股份有限公司（以 下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司 法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司股 东大会规则》（以下简称"《股东会规则》"）等现行有效的法律、行政法规、 部门规章、规范性文件（以下简称"法律法规"）以及《联化科技股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，指派本所律师对公司2024 年度股东大会（以下简称"本次股东大会"）进行见证，并依法出具本法律意见 书。 为出具本法律意见书，本所指派律师见证了本次股东大会，查阅了公司提供 的与本次股东大会有关的文件和资料 ...